Q-omics provides the consensus-scored HLA-DPB2 profile across patient tissues and cancer cell-line models. HLA-DPB2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, HLA-DPB2 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, HLA-DPB2 RNA expression shows 11,385 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight SKCM, KIRC, and HNSC as cancer lineages where HLA-DPB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HLA-DPB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HLA-DPB2 survival associations across molecular data types. HLA-DPB2 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HLA-DPB2 RNA expression–survival associations across cancer types. High HLA-DPB2 expression shows unfavorable associations in UVM, LGG, LAML, READ and MESO, but favorable associations in SKCM. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for HLA-DPB2 RNA expression.
This table summarizes HLA-DPB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HLA-DPB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HLA-DPB2 shows higher tumor expression in KIRC, STAD, THCA, BRCA and KIRP. The KIRC box plot shows higher HLA-DPB2 RNA expression in tumor versus normal tissue (log2 FC = +1.675, t-test p < 0.001).
This table shows molecular features associated with HLA-DPB2 in patient tissues and cancer cell lines. In patient samples, HLA-DPB2 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
